SRDX Surmodics PE ratio, current and historical analysis
The current PE ratio of SRDX can't be determined, as the TTM EPS of -$0.82 is negative. The most recent PE ratio recorded for Surmodics was 30.56 in March 2024.
SRDX PE ratio history
Over the last ten years, the average PE ratio of Surmodics has been 158.73. Over the past ten years, SRDX's PE ratio was at its highest in the Dec 2020 quarter at 870.4, with a price of $43.52 and an EPS of $0.05. The Sep 2015 quarter recorded the bottom point at 23.74, with a price of $21.84 and an EPS of $0.92.
Surmodics PE ratio by year
Maximum annual increase: 506.08% in 2020
Maximum annual decrease: -63.13% in 2021
| Year | PE ratio | Change |
|---|---|---|
| 2024 | N/A | N/A |
| 2023 | N/A | N/A |
| 2022 | N/A | N/A |
| 2021 | 179.35 | -63.13% |
| 2020 | 486.38 | 506.08% |
| 2019 | 80.25 | N/A |
| 2018 | N/A | N/A |
| 2017 | 103.33 | 164.41% |
| 2016 | 39.08 | 64.62% |
| 2015 | 23.74 | 15.02% |
SRDX average PE ratio chart
SRDX PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| ALKS Alkermes plc | 14.32 | $4.66B |
| JNJ Johnson & Johnson | 25.73 | $373.59B |
| A Agilent Technologies Inc | 27.65 | $38.46B |
| TMO Thermo Fisher Scientific Inc | 32.1 | $196.32B |
| ABT Abbott Laboratories | 35.68 | $204.25B |
| NKTR Nektar Therapeutics | N/A | $193.68M |
| ENZ Enzo Biochem Inc | N/A | $50.68M |
| HRTX Heron Therapeutics Inc | N/A | $162.74M |
| SRDX Surmodics Inc | N/A | $563.44M |
Frequently asked questions
What is Surmodics's PE ratio?
The current price to earnings ratio of SRDX can't be calculated, as its EPS of -$0.82 is negative.
What is the 5-year average PE ratio for Surmodics (SRDX)?
The 5-year average PE ratio for SRDX stock is 259.82.
What is the highest PE ratio for SRDX?
Over the last ten years, the quarterly PE ratio reached a historic high of 870.4 in the Dec 2020 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.